ARKG stock forecast, quote, news & analysis

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Teladoc Health (NYSE:TDOC), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

The average market capitalization across the ARK Genomic Revolution ETF ETF is 99.48B. The market cap for tickers in the group ranges from 9.84M to 3.48T. NVDA holds the highest valuation in this group at 3.48T. The lowest valued company is SNTI at 9.84M.

The average weekly price growth across all stocks in the ARK Genomic Revolution ETF ETF was -12%. For the same ETF, the average monthly price growth was -9%, and the average quarterly price growth was -15%. NTRA experienced the highest price growth at 9%, while MASS experienced the biggest fall at -33%.

The average weekly volume growth across all stocks in the ARK Genomic Revolution ETF ETF was 44%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was -5%